Effect of Minoxidil for Androgenetic Alopecia
For adult androgenetic alopecia, apply topical minoxidil 5% solution or foam twice daily (1 mL per application) directly to the affected scalp area, which prolongs anagen phase, converts vellus hairs to terminal hairs, and produces clinically meaningful hair regrowth starting at 2-4 months. 1, 2
Mechanism of Action
Minoxidil works through three primary pathways that directly address the pathophysiology of androgenetic alopecia:
- Prolongs the anagen (growth) phase of the hair cycle
- Triggers telogen-to-anagen transition, reactivating dormant follicles
- Transforms vellus (miniaturized) hairs into terminal (thick) hairs 1
These effects require conversion to minoxidil sulfate by follicular sulfotransferase 1A1 enzymes in the outer root sheath. Individual response variability is largely explained by differences in sulfotransferase activity—patients with higher enzyme activity respond better, though no practical test currently exists to predict this 1.
Recommended Dosing
Topical Minoxidil (FDA-Approved)
For both men and women, use 5% formulation twice daily for superior results despite FDA labeling historically recommending 5% for men and 2% for women—this distinction is outdated as safety and efficacy of 5% twice daily in women has been proven 1. The 5% concentration produces 45% more hair regrowth than 2% at 48 weeks 3.
Application technique matters:
- Apply 1 mL directly to dry scalp in the affected area
- Allow 4 hours before washing for optimal absorption (75% absorbs within first 4 hours) 1, 2
- Avoid blow-drying immediately after application (accounts for 50% absorption loss) 1
- Wash hands immediately after finger application to prevent unwanted facial hair growth 2
- Allow 2-4 hours drying time before bed to prevent pillow staining 2
Critical caveat: Less than 5% of topical minoxidil is absorbed systemically, and applying more than twice daily does not increase efficacy 1.
Low-Dose Oral Minoxidil (Off-Label)
For patients with widespread scalp involvement or poor compliance with topical application, low-dose oral minoxidil (LDOM) is preferred 1:
- Men: Start 2.5 mg/day (range 1.25-5 mg/day)
- Women: Start 1.25 mg/day (range 0.625-5 mg/day) 4
Two controlled trials showed no statistically significant difference in efficacy between 5% topical minoxidil 1-2 times daily and 1 mg oral minoxidil 1. Oral formulation offers advantages of ease of use, no effect on hairstyle, better compliance, and bypasses limitations of cutaneous absorption 1.
Timeline and Expectations
Initial shedding (first 2 weeks): Expect temporary increased hair loss as old telogen hairs are shed to make room for new anagen hairs—this is a positive sign the medication is working 2.
Early response (2 months): Some patients see initial results, particularly with 5% topical formulation which produces earlier response than 2% 3.
Adequate trial (4 months minimum): Most men require at least 4 months before visible results 2. If no improvement by 4 months, discontinue treatment 2.
Peak effect (1 year): Hair regrowth tends to peak at 12 months 5.
Long-term maintenance: Hair counts remain above baseline through 48 weeks in clinical trials 3. Five-year data shows gradual decline after year 1 but maintenance of nonvellus hairs beyond baseline persists 5. Continuous use is mandatory—stopping treatment results in loss of newly regrown hair within 3-4 months 2.
Side Effects
Topical Minoxidil
Common (well-tolerated):
- Scalp itching and dryness (75% of patients) 6
- Local irritation (more common with 5% than 2%) 3
- Allergic contact dermatitis (rare) 1
Unwanted hair growth:
- Facial/body hypertrichosis occurs rarely but is reversible with discontinuation 2
- Minimize risk by: limiting application to scalp only, washing hands immediately after application, allowing complete drying before bed 2
Important: Topical minoxidil is flammable due to alcohol content—keep away from fire or flame 2.
Low-Dose Oral Minoxidil
Common:
- Dose-dependent hypertrichosis (24% incidence) 4
- Transient shedding (16-22%) 4
- Headaches (20%) 6
- Dizziness (15%) 6
- Mild peripheral edema (2-5%) 4, 6
Rare but serious: Pericardial effusion (rare at doses used for alopecia) 4.
Contraindications for oral minoxidil: Pericardial disease, uncontrolled hypertension, pregnancy, breastfeeding 4.
Clinical Efficacy
The 5% topical formulation is clearly superior to 2% and placebo, with marked effect magnitude 3. At 32 weeks, terminal hair density increases by approximately 47-57% across treatment modalities 6. Response is better in patients with:
- Shorter duration of hair loss
- Less extensive hair loss at baseline
- Vertex (crown) involvement rather than frontal recession 2
Realistic expectations: Complete hair restoration is unlikely. Not everyone responds to minoxidil due to variable sulfotransferase activity 2. Approximately 17.5% of patients show significant improvement (>50%), while another 17.5% improve minimally (<10%) 7.
Adjunctive Therapies
Efficacy increases with concomitant use of:
- Microneedling
- Low-level laser therapy
- Platelet-rich plasma (PRP with topical minoxidil shows 57% increase in terminal hair density vs. 48% with topical alone) 6
- Topical tretinoin (enhances absorption) 1
Concomitant topical steroids decrease systemic absorption while increasing local concentration 1.
Formulation Selection
Choose topical minoxidil (5% solution or foam) for:
- Hair loss limited to central scalp or patchy areas
- First-line therapy in both men and women
Choose low-dose oral minoxidil for:
- Widespread scalp involvement
- Poor compliance with topical application
- Failure to respond to topical therapy (may indicate low follicular sulfotransferase activity)
- Patient preference for ease of use 1
Note: Foam formulation has lower systemic bioavailability than solution but both are effective 1.